Who are we ?

Thanks to the experience of our founder, Gilles Bos, and that of our collaborators acquired at Corneal, Allergan, Anteis, Aptissen, etc. we are confident that we have all the tools to make SyrHA's vision a reality.
Our vision

Our Vision 

Medical devices based on hyaluronic acid are constantly being improved. We strive to bring our technical expertise and make your hyaluronic-acid-based medical devices  safer and more effective.

Our ambition

We seek to capitalize on our expertise in hyaluronic acid and our  raw materials of high quality and purity.  So when your formulas are combined with our proprietary manufacturing technology, we add value to the development and implementation of your products. 

In collaboration with its partners, SyrHA wishes to  contribute to the marketing of innovative products for uses as  diverse as aesthetic, ophthalmological and musculoskeletal.

Our value

Our values

We pride ourselves on our teamwork, transparency, dedication to Swiss quality standards, open-mindedness, efficiency, entrepreneurial spirit and strong customer service.

Our story

  • 1992

    OVD d’origine animale
    Développement Viscorneal
  • 2000

    Développement de juvederm
  • 2005

    Développement d’esthélis
  • 2011

    Belotero certifié FDA
  • 2013

    Développement de synolis
  • 2018

    SyrHatech démarre ses activités de CDMO
  • 2019

    Développement de INTEXHYA
  • 2020

    Syrha GMP / ISO 13485 en tant que CDMO

Explore our environment

  • Company

    They Trust SyrHA : The Excellence of a CDMO

    At SyrHA, we believe that the cornerstone of our success is the unwavering trust that…

    Clients testimonials
  • Company

    Announcing strategic partnership : SyrHA the CDMO and ISHAS organization

    We are pleased to inform you that SyrHA has joined the International Society for Hyaluronic…

  • Company

    CDMO: Evolution of their role

    Innovative biopharmaceutical companies are increasingly engaging in strategic partnerships with CDMOs, whereas in the past,…

    CDMO: Evolution of their role
  • Company

     Join us at IMCAS Paris! 

    We’re delighted to announce that our team will be taking part in the IMCAS 2024…

    IMCAS 2024 World Congress in Paris
  • Company

    SyrHATech is thrilled to install its new autoclave!

    In the field of sterile medical device manufacturing, the terminal sterilization of your products is…

    SyrHATech new autoclave
  • Company

    SyrHATech goes to CPHI Barcelona – from 10/24 to 10/26

    The CPHI (Convention on Pharmaceutical Ingredients) is the reference event for the pharmaceutical industry. Itinerant…

    CPHI Barcelona 2023
  • Company

    Inauguration of Syrhatech’s new premises in Geneva

    The Syrhatech team was delighted to share a convivial moment on its terrace on the…

    Inauguration of Syrhatech's new premises in Geneva
  • Company

    Development of a specific syringe for wrinkle filler

    Our customer contacts us to validate the design of a syringe made of plastic by…

  • Company

    Development of an innovative gel with very high concentration

    Our client contacts us to industrialize a new manufacturing technique, compatible with the objectives of…

  • Company

    Technology transfer

    Our team relies on its many years of experience and past successes, to prepare and…

    Syrhatech - technology transfer